into the Risk-RA clinical research program, and followed-up by our multidisciplinary rheumatology team. A total of 64 patients with complete US records were included between years 2015!2016. Our patient demographics were 84% (n 54/64) females, mean age 49 (range 22-82) years, median relative ACPA (times cut-off) 26 (range 1-174) titer, median visual analogue scale (VAS) pain 30, median VAS patient global 28 and median C-reactive protein was 1 (0-20) at inclusion. Hand (Wrists, MCP's, PIP's, DIP's) and feet joints were USevaluated for synovial hypertrophy, hyperemia and bone erosions. The presence of wrist (compartments 1-6) and finger (flexor and extensor) tenosynovitis were assessed. Data from inclusion!follow-up visits until September 2017 were analysed. SPSS software version 25 was used (Univariate, Chisquare, T-test and Mann Whitney U-test) for comparisons. Results At inclusion, none of the 64 patients had any signs of active joint inflammation. However, ultrasound changes for tenosynovitis were seen in 7 out of 64 patients, 3 of who also presented with mild hypertrophy without Doppler activity and one patient with mild Doppler hyperemia (without hypertrophy), and none with bone erosions at inclusion. Among all tendons evaluated bilaterally, tenosynovitis of the Extensor Carpi Ulnaris (ECU) wrist tendons (4 of 7 patients) and the 2nd finger flexor-tendons (3 of 7 patients) were most commonly affected.
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TOLL-LIKE RECEPTOR 9 INFLUENCES INFLAMMATORY ARTHRITIS AND OSTEOCLASTOGENESIS
Introduction Release and insufficient removal of endogenous nucleic acids may be involved in triggering autoimmune reactions important in the initiation of systemic autoimmune diseases including rheumatoid arthritis (RA). Nucleic acid sensing molecules, such as the endosomal Toll-like receptors (TLRs) 7 and 9, have been linked to pathogenic autoimmune processes, but their role in RA is less clear. Objectives To gain more insight into the role of TLR9 in autoimmune arthritis, TLR9 inhibition was investigated in rats with pristane-induced arthritis (PIA). To further investigate TLR9 involvement, streptococcal cell wall (SCW) arthritis was induced in TLR9 -/-mice. Methods Arthritis was induced in mice with SCW lysates and in rats with the mineral oil pristane. Rats were treated with a TLR9 antagonist, starting before disease induction. Arthritis was scored using established scoring systems, inflammation and bone erosion was quantified by histological analysis of the paws. Levels of aÀ1-acid-glycoprotein (AGP), rheumatoid factor (RF) and IL-6 in sera were analysed. The role of TLR9 in osteoclast differentiation was investigated in vitro. Results In PIA, which is T cell-dependent, the TLR9 antagonist reduced arthritis severity by~50%. This was accompanied by a reduction of AGP, IL-6 and RF in the sera of these animals. In addition, TLR9 inhibition led to reduced inflammation, bone erosion and cartilage degradation in the paws. Moreover, the T cell-dependent chronic phase of SCW arthritis was significantly suppressed in TLR9 -/-mice. Remarkably, TLR7 and TLR9 mRNA levels strongly differed in the course of in vitro osteoclastogenesis. Whereas TLR7 expression did not change throughout osteoclastogenesis, expression of TLR9 was higher in precursor cells than in mature osteoclasts and stimulation with a TLR9 agonist (CpG) completely inhibited osteoclastogenesis.
Conclusions The results suggest a crucial role for TLR9 in the T cell-dependent phases of PIA and SCW arthritis and thus an important involvement of the DNA (CpG) recognising TLR9 in the induction of arthritogenic autoimmune reactions. In addition, TLR9 also seems to play a role in the initiation of osteoclast differentiation which needs to be further elucidated in future experiments. Introduction Three monocyte subsets have been described based on their CD14 and CD16 expression profiles, the subpopulation CD14 + CD16 + being expanded in rheumatoid arthritis (RA) patients. Macrophages contribute in situ to the RA pathogenesis. They can display various states of activation or « polarisation ». Two distinct states of polarisation for macrophages have been recognised: the 'classically activated macrophage phenotype' (M1) and the 'alternatively activated macrophage phenotype' (M2). To sum-up, M1 are considered to be pro-inflammatory and M2 to be regulatory and antiinflammatory. Objectives Here, we have assessed monocytes subsets and their capacity of differentiation into M2 or M1 macrophages in RA patients and controls.
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MEMBRANE TNF EXPRESSION ON MONOCYTES AND DIFFERENTIATION OF MONOCYTES INTO M2-M1 MACROPHAGES: 2 NEW BIOMARKERS OF RHEUMATOID ARTHRITIS
Methods PBMCs were isolated and we first determined monocytes subpopulations and looked at expression of membrane TNF (mTNF). After negative selection of monocytes, Macrophages were Derived from Monocytes(MDM) by 7 days of culture in the presence of M-CSF (M2 differentiation) or GM-CSF (M1 differentiation). Expression of total macrophages markers (CD11b and CD71) and the M2 macrophage polarisation markers (CD163 and CD206) were evaluated. Introduction Anti-tumour therapy with immune checkpoint inhibitors for programmed-death 1 receptor (PD1), such as nivolumab is often accompanied by immune-related adverse events (irAE). The cellular and molecular mechanisms underlying this phenomenon are not defined yet. Interaction of PD-1 with its ligand (PD-L1) mediates potent inhibitory signals to hinder proliferation and effector function of T cells. Interruption of PD1:PD-L1 interaction by nivolumab during antitumour therapy might therefore amplify T cell receptor (TCR) signalling and facilitate the development of a pro-inflammatory autoimmune response. Objectives To investigate the impact of PD1 inhibition on intracellular signalling mechanisms down-stream of the TCR such as calcium (Ca 2+ ) influx and activation of mitogen-activated protein kinases (MAPK) pathway and to assess the effect of PD1 inhibition on T cell effector function by evaluating the cytokine profile of the nivolumab-treated T cells. Methods CD4 memory T cells were stimulated with anti-CD3 and anti-CD28 in the presence of nivolumab for 24 hour.
Afterwards intracellular Ca 2+ influx in response to ionomycin was assessed by flow cytometry following loading the cells with Fluo-8. Expression of proteins involved in store-operated Ca 2+ entry (SOCE), stromal activation molecule (STIM) 1, an activator of Ca 2+ release-activated Ca 2+ (CRAC) channels, and Orai1, a component of CRAC channels was determined by TaqMan real-time PCR. Phosphorylation of extracellular signal-regulated kinase 1 and 2 (Erk1/2) in response to anti-CD3/28 was determined by intracellular flow cytometry. The cytokine profile of nivolumab-treated cells was assessed after four-day culture by intracellular flow cytometry. Results Treatment of CD4 T cells with nivolumab led to a pronounced increase of the ionomycin-mediated Ca 2+ influx. At the same time expression of SOCE proteins, STIM1 and Orai1, was significantly up regulated in the nivolumab-treated cells. Phosphorylation of Erk1/2 in response to short anti-CD3/CD28 restimulation was almost twice as high in CD4 T cells cultured with as without nivolumab. Finally nivolumabtreated cells contained higher frequencies of IL-17-producing T cells (Th17 cells). Conclusions Interruption of PD1:PD-L1 interaction by nivolumab activate SOCE and promotes Erk1/2 activation. Both T cell signalling pathways are essential for a proper mounting an immune response. Their deregulation might therefore precede an abnormal T cell response as shown for example by increased Th17 cell frequency and facilitate the onset of autoimmune phenomena such as irAE.
Introduction Smoking is a risk factor for the development of rheumatoid arthritis (RA) and associates with positivity for disease specific anti cyclic citrullinated peptide (aCCP) antibodies. It is not known exactly how smoking promotes autoimmunity but we have previously demonstrated that smoking limits the expression of the T cell co-inhibitory receptor programmed death-1 (PD-1).
1
Objectives To investigate if smoking can interfere with the interaction between PD-1 and its ligand by influencing the serum levels of soluble PD-1 ligand 1 (sPD-L1). Methods Serum samples were collected from 254 RA patients and 168 healthy controls with known smoking status and analysed with ELISA for levels of sPD-L1 and inflammatory cytokines IL-6 and IL-1b. Fc-receptor mRNA expression analysis of peripheral blood monocytes (PBMC) from a group of 10 healthy controls and 15 RA patients was done by qPCR. Results In RA patients current smokers had 5 times lower median serum levels of sPD-L1 compared to never smokers (p=0.027). This difference persisted in former smokers that quit smoking <25 years ago (p=0.0086). Expectedly, sPD-L1
